{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:07:29Z","timestamp":1787771249291,"version":"build-2784847793"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"crossref","award":["20767"],"award-info":[{"award-number":["20767"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"name":"\u201cRicerca Corrente Fondazione IRCCS Policlinico San Matteo","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10238-020-00615-6","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T14:02:46Z","timestamp":1581516166000},"page":"321-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["HCV infection and non-Hodgkin lymphomas: an evolving story"],"prefix":"10.1007","volume":"20","author":[{"given":"Irene","family":"Defrancesco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Zerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rattotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Paulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-991X","authenticated-orcid":false,"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"issue":"8","key":"615_CR1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/rheumatology\/kem132","volume":"46","author":"D Saadoun","year":"2007","unstructured":"Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology. 2007;46(8):1234\u201342.","journal-title":"Rheumatology"},{"issue":"8","key":"615_CR2","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2005-09-3679","volume":"107","author":"F Suarez","year":"2006","unstructured":"Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034\u201344.","journal-title":"Blood"},{"issue":"4","key":"615_CR3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","volume":"24","author":"M Dreyling","year":"2013","unstructured":"Dreyling M, Thieblemont C, Gallamini A, et al. Esmo consensus conferences: guidelines on malignant lymphoma. Part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24(4):857\u201377.","journal-title":"Ann Oncol"},{"issue":"5","key":"615_CR4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.autrev.2017.03.004","volume":"16","author":"AL Zignego","year":"2017","unstructured":"Zignego AL, Ramos-Casals M, Ferri C, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16(5):523\u201341.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"615_CR5","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2002-10-3230","volume":"102","author":"A Mele","year":"2003","unstructured":"Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood. 2003;102(3):996\u20139.","journal-title":"Blood"},{"issue":"6","key":"615_CR6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10552-009-9316-0","volume":"20","author":"L Goldman","year":"2009","unstructured":"Goldman L, Ezzat S, Mokhtar N, et al. Viral and non-viral risk factors for non-Hodgkin\u2019s lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control. 2009;20(6):981\u20137.","journal-title":"Cancer Causes Control"},{"issue":"6","key":"615_CR7","first-page":"1723","volume":"125","author":"JP Gisbert","year":"2003","unstructured":"Gisbert JP, Garc\u00eda-Buey L, Pajares MJ, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin\u2019s lymphoma: systematic. Rev Meta-Anal Gastroenterol. 2003;125(6):1723\u201332.","journal-title":"Rev Meta-Anal Gastroenterol"},{"issue":"1","key":"615_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.20205","volume":"111","author":"E Negri","year":"2004","unstructured":"Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin\u2019s lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer. 2004;111(1):1\u20138.","journal-title":"Int J Cancer"},{"issue":"2","key":"615_CR9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4254\/wjh.v8.i2.107","volume":"8","author":"G Pozzato","year":"2016","unstructured":"Pozzato G, Mazzaro C, Dal Maso L, et al. Hepatitis C virus and non-Hodgkin\u2019s lymphomas: meta-analysis of epidemiology data and therapy options. World J Hepatol. 2016;8(2):107\u201316.","journal-title":"World J Hepatol"},{"issue":"4","key":"615_CR10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","volume":"6","author":"S De Sanjose","year":"2008","unstructured":"De Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol. 2008;6(4):451\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"615_CR11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ajh.23889","volume":"90","author":"JM Michot","year":"2015","unstructured":"Michot JM, Canioni D, Driss H, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015;90(3):197\u2013203.","journal-title":"Am J Hematol"},{"issue":"5","key":"615_CR12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ajh.21065","volume":"83","author":"MC Goldaniga","year":"2008","unstructured":"Goldaniga MC, Ferrario A, Cortelazzo S, et al. A multicenter retrospective clinical study of CD5\/CD10-negative chronic B cell leukemias. Am J Hematol. 2008;83(5):349\u201354.","journal-title":"Am J Hematol"},{"issue":"12","key":"615_CR13","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","volume":"120","author":"Y Kawamura","year":"2007","unstructured":"Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with Hepatitis C. Am J Med. 2007;120(12):1034\u201341.","journal-title":"Am J Med"},{"issue":"3","key":"615_CR14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/apt.15101","volume":"49","author":"TH Su","year":"2019","unstructured":"Su TH, Liu CJ, Tseng TC, et al. Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2019;49(3):331\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"615_CR15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","volume":"67","author":"P Mahale","year":"2018","unstructured":"Mahale P, Engels EA, Li R, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67(3):553\u201361.","journal-title":"Gut"},{"issue":"11","key":"615_CR16","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/apt.15240","volume":"49","author":"HB El-Serag","year":"2019","unstructured":"El-Serag HB, Christie IC, Puenpatom A, et al. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 2019;49(11):1442\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"615_CR17","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/liv.14119","volume":"39","author":"M Masarone","year":"2019","unstructured":"Masarone M, Persico M. Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis. Liver Int. 2019;39(7):1292\u2013306.","journal-title":"Liver Int"},{"issue":"10","key":"615_CR18","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood.V96.10.3578","volume":"96","author":"V De Re","year":"2000","unstructured":"De Re V, De Vita S, Marzotto A, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus\u2014Associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor\u2014producing cells that occur mainly in type II cryoglobulinemia. Blood. 2000;96(10):3578\u201384.","journal-title":"Blood"},{"issue":"4","key":"615_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jmv.1890450411","volume":"45","author":"R Lesniewski","year":"1995","unstructured":"Lesniewski R, Johnson R, Scheffel J, et al. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J Med Virol. 1995;45(4):415\u201322.","journal-title":"J Med Virol"},{"issue":"13","key":"615_CR20","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1128\/JVI.79.13.8079-8089.2005","volume":"79","author":"K Machida","year":"2005","unstructured":"Machida K, Cheng KT-H, Pavio N, Sung VM-H, Lai MMC. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin Gene in B cells. J Virol. 2005;79(13):8079\u201389.","journal-title":"J Virol"},{"issue":"4","key":"615_CR21","doi-asserted-by":"crossref","first-page":"e18933","DOI":"10.1371\/journal.pone.0018933","volume":"6","author":"Z Chen","year":"2011","unstructured":"Chen Z, Zhu Y, Ren Y, et al. Hepatitis C virus protects human B lymphocytes from fas-mediated apoptosis via E2-CD81 engagement. PLoS ONE. 2011;6(4):e18933.","journal-title":"PLoS ONE."},{"issue":"1","key":"615_CR22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/1521-4141(200101)31:1<166::AID-IMMU166>3.0.CO;2-L","volume":"31","author":"A Wack","year":"2001","unstructured":"Wack A, Soldaini E, Tseng CTK, et al. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur J Immunol. 2001;31(1):166\u201375.","journal-title":"Eur J Immunol"},{"issue":"12","key":"615_CR23","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1073\/pnas.0303971101","volume":"101","author":"K Machida","year":"2004","unstructured":"Machida K, Cheng KTN, Sung VMH, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A. 2004;101(12):4262\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"615_CR24","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/leu.2012.29","volume":"26","author":"J Peveling-Oberhag","year":"2012","unstructured":"Peveling-Oberhag J, Crisman G, Schmidt A, et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia. 2012;26(7):1654\u201362.","journal-title":"Leukemia"},{"issue":"21","key":"615_CR25","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJM199211193272104","volume":"327","author":"V Agnello","year":"1992","unstructured":"Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490\u20135.","journal-title":"N Engl J Med"},{"issue":"3","key":"615_CR26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","volume":"116","author":"F Dammacco","year":"2010","unstructured":"Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-\u03b1, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343\u201353.","journal-title":"Blood"},{"issue":"4","key":"615_CR27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/apt.14845","volume":"48","author":"L Gragnani","year":"2018","unstructured":"Gragnani L, Cerretelli G, Lorini S, et al. Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. Aliment Pharmacol Ther. 2018;48(4):440\u201350.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"615_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-018-0536-z","volume":"19","author":"F Dammacco","year":"2019","unstructured":"Dammacco F, Lauletta G, Russi S, et al. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med. 2019;19(1):1\u201321.","journal-title":"Clin Exp Med"},{"issue":"1","key":"615_CR29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.165.1.101","volume":"165","author":"G Monti","year":"2005","unstructured":"Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med. 2005;165(1):101\u20135.","journal-title":"Arch Intern Med"},{"issue":"2","key":"615_CR30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood.V90.2.776.776_776_782","volume":"90","author":"S De Vita","year":"1997","unstructured":"De Vita S, Sacco C, Sansonno D, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood. 1997;90(2):776\u201382.","journal-title":"Blood"},{"key":"615_CR31","volume-title":"Lymphomas associated with chronic hepatitis C virus infection: a prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network","author":"S Rattotti","year":"2019","unstructured":"Rattotti S, Ferretti VV, Rusconi C, et al. Lymphomas associated with chronic hepatitis C virus infection: a prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. Oncol: Hematol; 2019."},{"issue":"17","key":"615_CR32","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","volume":"127","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127(17):2072\u201381.","journal-title":"Blood"},{"issue":"12","key":"615_CR33","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","volume":"107","author":"L Arcaini","year":"2006","unstructured":"Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107(12):4643\u20139.","journal-title":"Blood"},{"issue":"1","key":"615_CR34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/blood-2004-05-1711","volume":"105","author":"D Saadoun","year":"2005","unstructured":"Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood. 2005;105(1):74\u20136.","journal-title":"Blood"},{"issue":"5","key":"615_CR35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdl027","volume":"17","author":"AJM Ferreri","year":"2006","unstructured":"Ferreri AJM, Viale E, Guidoboni M, et al. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol. 2006;17(5):769\u201372.","journal-title":"Ann Oncol"},{"issue":"2","key":"615_CR36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2141.2006.06437.x","volume":"136","author":"L Arcaini","year":"2007","unstructured":"Arcaini L, Paulli M, Burcheri S, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol. 2007;136(2):301\u20134.","journal-title":"Br J Haematol"},{"issue":"6","key":"615_CR37","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/annonc\/mdp454","volume":"21","author":"M Paulli","year":"2009","unstructured":"Paulli M, Arcaini L, Lucioni M, et al. Subcutaneous \u201clipoma-like\u201d B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Ann Oncol. 2009;21(6):1189\u201395.","journal-title":"Ann Oncol"},{"issue":"9","key":"615_CR38","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","volume":"209","author":"D Rossi","year":"2012","unstructured":"Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209(9):1537\u201351.","journal-title":"J Exp Med"},{"issue":"4","key":"615_CR39","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V97.4.1023","volume":"97","author":"CH Chan","year":"2001","unstructured":"Chan CH, Hadlock KG, Foung SKH, Levy S. VH1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood. 2001;97(4):1023\u20136.","journal-title":"Blood"},{"issue":"2","key":"615_CR40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","volume":"347","author":"O Hermine","year":"2002","unstructured":"Hermine O, Lefr\u00e8re F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89\u201394.","journal-title":"N Engl J Med"},{"issue":"3","key":"615_CR41","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","volume":"23","author":"D Vallisa","year":"2005","unstructured":"Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin\u2019s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23(3):468\u201373.","journal-title":"J Clin Oncol"},{"issue":"9","key":"615_CR42","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/annonc\/mdl131","volume":"17","author":"C Visco","year":"2006","unstructured":"Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol. 2006;17(9):1434\u201340.","journal-title":"Ann Oncol"},{"issue":"6","key":"615_CR43","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2005.01.5016","volume":"24","author":"C Besson","year":"2006","unstructured":"Besson C, Cantoni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 groupe d\u2019etude des lymphomes de l\u2019adulte programs. J Clin Oncol. 2006;24(6):953\u201360.","journal-title":"J Clin Oncol"},{"issue":"1","key":"615_CR44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/10428190701732861","volume":"49","author":"BB Park","year":"2008","unstructured":"Park BB, Kim JS, Lee YY, et al. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(1):88\u201394.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"615_CR45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3324\/haematol.2013.094318","volume":"99","author":"M Merli","year":"2014","unstructured":"Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99(3):489\u201396.","journal-title":"Haematologica"},{"issue":"11","key":"615_CR46","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/bjc.2017.345","volume":"117","author":"C Visco","year":"2017","unstructured":"Visco C, Wang J, Tisi MC, et al. Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. Br J Cancer. 2017;117(11):1685\u20138.","journal-title":"Br J Cancer"},{"issue":"1","key":"615_CR47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2013.03.018","volume":"59","author":"J Peveling-Oberhag","year":"2013","unstructured":"Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59(1):169\u201377.","journal-title":"J Hepatol"},{"issue":"2","key":"615_CR48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3324\/haematol.2014.116855","volume":"100","author":"L Arcaini","year":"2015","unstructured":"Arcaini L, Rossi D, Lucioni M, et al. The notch pathway is recurrently mutated in diffuse large B-Cell lymphoma associated with hepatitis c virus infection. Haematologica. 2015;100(2):246\u201352.","journal-title":"Haematologica"},{"issue":"6","key":"615_CR49","doi-asserted-by":"crossref","first-page":"e0156384","DOI":"10.1371\/journal.pone.0156384","volume":"11","author":"D Canioni","year":"2016","unstructured":"Canioni D, Michot JM, Rabiega P, et al. In situ hepatitis C NS3 protein detection is associated with high grade features in hepatitis C-associated B-cell non-Hodgkin lymphomas. PLoS ONE. 2016;11(6):e0156384.","journal-title":"PLoS ONE."},{"issue":"1","key":"615_CR50","first-page":"105","volume":"13","author":"GM El-Sayed","year":"2006","unstructured":"El-Sayed GM, din Mohamed WSE, Nouh MA, Moneer MM, El-Mahallawy HA. Viral genomes and antigen detection of hepatitis B and C viruses in involved lymph nodes of Egyptian non-Hodgkin\u2019s lymphoma patients. Egypt J Immunol. 2006;13(1):105\u201314.","journal-title":"Egypt J Immunol"},{"issue":"24","key":"615_CR51","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","volume":"116","author":"D Ennishi","year":"2010","unstructured":"Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116(24):5119\u201325.","journal-title":"Blood"},{"issue":"2","key":"615_CR52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2008.07565.x","volume":"145","author":"C Mazzaro","year":"2009","unstructured":"Mazzaro C, De Re V, Spina M, et al. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol. 2009;145(2):255\u20137.","journal-title":"Br J Haematol"},{"issue":"7","key":"615_CR53","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","volume":"25","author":"L Arcaini","year":"2014","unstructured":"Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404\u201310.","journal-title":"Ann Oncol"},{"issue":"11","key":"615_CR54","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.V106.11.2447.2447","volume":"106","author":"P Musto","year":"2005","unstructured":"Musto P, Dell\u2019Olio M, La Sala A, Mantuano S, Cascavilla N. Diffuse B-large cell lymphomas (DBLCL) with hepatitis-C virus (HCV) infection: clinical outcome and preliminary results of a pilot study combining R-CHOP with antiviral therapy. Blood. 2005;106(11):2447.","journal-title":"Blood"},{"issue":"4","key":"615_CR55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jhep.2008.06.025","volume":"49","author":"V La Mura","year":"2008","unstructured":"La Mura V, De Renzo A, Perna F, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin\u2019s lymphoma. J Hepatol. 2008;49(4):557\u201363.","journal-title":"J Hepatol"},{"issue":"1","key":"615_CR56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","volume":"67","author":"M Persico","year":"2018","unstructured":"Persico M, Aglitti A, Caruso R, et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus\u2013infected patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma. Hepatology. 2018;67(1):48\u201355.","journal-title":"Hepatology"},{"issue":"20","key":"615_CR57","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889\u201398.","journal-title":"N Engl J Med"},{"issue":"21","key":"615_CR58","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and Ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993\u20132001.","journal-title":"N Engl J Med"},{"key":"615_CR59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","volume":"36","author":"T Asselah","year":"2016","unstructured":"Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36:47\u201357.","journal-title":"Liver Int"},{"issue":"2","key":"615_CR60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"JM Pawlotsky","year":"2018","unstructured":"Pawlotsky JM, Negro F, Aghemo A, et al. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"issue":"1","key":"615_CR61","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jhep.2014.09.031","volume":"62","author":"R Rossotti","year":"2015","unstructured":"Rossotti R, Travi G, Pazzi A, et al. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3\/NS4A inhibitor-based treatment. A case report. J Hepatol. 2015;62(1):234\u20137.","journal-title":"J Hepatol"},{"issue":"15","key":"615_CR62","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2014-12-618652","volume":"125","author":"P Sultanik","year":"2015","unstructured":"Sultanik P, Klotz C, Brault P, Pol S, Mallet V. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood. 2015;125(15):2446\u20137.","journal-title":"Blood"},{"issue":"1","key":"615_CR63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.14309\/crj.2015.104","volume":"3","author":"LY Lim","year":"2015","unstructured":"Lim LY, La D, Cserti-Gazdewich CM, Shah H. Lymphoma Remission by Interferon-Free HCV Eradication Without Chemotherapy. ACG Case Rep J. 2015;3(1):69\u201370.","journal-title":"ACG Case Rep J"},{"issue":"21","key":"615_CR64","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","volume":"128","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527\u201332.","journal-title":"Blood"},{"key":"615_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0687-2","author":"M Frigeni","year":"2019","unstructured":"Frigeni M, Besson C, Visco C, et al. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2019. https:\/\/doi.org\/10.1038\/s41375-019-0687-2.","journal-title":"Leukemia"},{"issue":"1","key":"615_CR66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.21564","volume":"85","author":"L Arcaini","year":"2010","unstructured":"Arcaini L, Merli M, Passamonti F, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin\u2019s lymphomas. Am J Hematol. 2010;85(1):46\u201350.","journal-title":"Am J Hematol"},{"issue":"8","key":"615_CR67","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1634\/theoncologist.2018-0331","volume":"24","author":"M Merli","year":"2019","unstructured":"Merli M, Frigeni M, Alric L, et al. Direct-acting antivirals in hepatitis C virus-associated diffuse large B-cell lymphomas. Oncologist. 2019;24(8):e720\u20139.","journal-title":"Oncologist"},{"issue":"5","key":"615_CR68","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.dld.2018.10.019","volume":"51","author":"V Occhipinti","year":"2019","unstructured":"Occhipinti V, Farina L, Vigan\u00f2 M, et al. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma. Dig Liver Dis. 2019;51(5):719\u201323.","journal-title":"Dig Liver Dis"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-020-00615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-020-00615-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-020-00615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T14:12:44Z","timestamp":1722435164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-020-00615-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s10238-020-00615-6","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"29 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LA received advisory honoraria from Bayer, Celgene, Gilead, Roche, Sandoz, Verastem and research support from Gilead; RB received advisory and speakers bureau honoraria from AbbVie and MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}